Thalidomide-related toxicities experienced in a phase 3 trial of Total Therapy II. (A) Significantly higher incidence of grades 2 and 3 sensory neuropathy on thalidomide-containing treatment arm. (B) Significantly higher incidence of deep venous thrombosis (DVT) on thalidomide arm, which could be eliminated by prophylactic use of low-molecular-weight heparin (Lovenox; Aventis, Strasbourg, France) (C).